Welcome to our dedicated page for Vor Biopharma news (Ticker: VOR), a resource for investors and traders seeking the latest updates and insights on Vor Biopharma stock.
Vor Biopharma Inc. develops telitacicept for autoimmune diseases, with company updates centered on clinical development, financing, governance and employee equity compensation. Telitacicept is described by the company as a dual BAFF/APRIL inhibitor and novel dual-target fusion protein for autoantibody-driven conditions, with global Phase 3 programs in generalized myasthenia gravis and primary Sjögren’s disease.
Recurring news includes clinical-trial starts and data discussions, financial results and balance-sheet updates, private-placement financing, board appointments, investor-conference presentations and Nasdaq inducement grants under the Vor Biopharma Inc. 2023 Inducement Plan. Company announcements also reflect telitacicept regulatory status in China and global development across major autoimmune indications.
Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, announced that Dr. Robert Ang, the President and CEO, will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 2:20 PM ET. A live webcast will be available on the Company's website, with an archived replay following the conference. Vor Biopharma focuses on changing the standard of care for blood cancer patients by engineering hematopoietic stem cells for targeted therapies post-transplant.
Vor Biopharma (Nasdaq: VOR) announced participation in two virtual investor conferences. The first is the H.C. Wainwright BioConnect 2022, with a pre-recorded presentation available on January 10, 2022, starting at 7:00 AM ET. The second event is the 2022 B Riley Virtual Oncology Conference, featuring a live webcast fireside chat on January 27, 2022, at 10:30 AM ET. Both presentations will be accessible through the company’s website, along with archived replays.
Vor Biopharma focuses on engineering hematopoietic stem cells to improve blood cancer treatments.
Vor Biopharma (Nasdaq: VOR) announced that Dr. Robert Ang, the company's President and CEO, will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on December 6, 2021, at 12:40 PM ET. Investors can access a live webcast of the chat on the company’s website, with an archived replay available afterward. Vor Biopharma focuses on transforming care for blood cancer patients by engineering hematopoietic stem cells for targeted therapies following transplantation.
Vor Biopharma (Nasdaq: VOR) announced that Dr. Robert Ang, President and CEO, will participate in the Piper Sandler 33rd Virtual Annual Healthcare Conference. The conference is scheduled from November 30 to December 2, 2021. A pre-recorded presentation will be available on-demand starting November 22, 2021, at 10:00 am ET, accessible via the Investors section of Vor's website. Vor Biopharma focuses on engineering hematopoietic stem cells to improve treatments for blood cancers.
Vor Biopharma (Nasdaq: VOR) reported its Q3 2021 financial results, indicating a net loss of $18.6 million, up from $11.8 million in Q3 2020. The company is actively enrolling patients in its Phase 1/2a trial of VOR33 for AML, with initial data expected in H1 2022. VOR33 has received FDA Fast Track designation. Vor expanded its pipeline with a new multi-targeted treatment system and is progressing on its internal manufacturing facility, set to be operational in 2022. Cash and investments stood at $226 million, expected to fund operations into mid-2023.
Vor Biopharma (Nasdaq: VOR) has announced new data from its cell therapy platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), running from November 10-14, 2021, in Washington D.C. The research showcases a novel approach for treating acute myeloid leukemia (AML) using a cytokine tethered to T cells to enhance tumor cell killing. Vor also optimized a high-throughput fluorescent-protein platform for screening chimeric antigen receptor (CAR) constructs. The results aim to advance therapies targeting CD123-expressing leukemic cells.
Vor Biopharma (Nasdaq: VOR) announced participation in two virtual investor conferences featuring key executives. The Stifel 2021 Virtual Healthcare Conference will be held on November 15, 2021, at 4:00 PM ET, while the Evercore ISI 4th Annual HealthCONx Virtual Conference is scheduled for December 2, 2021, at 10:55 AM ET. Live webcasts for both events will be accessible via the company’s Investors section. Vor Biopharma focuses on engineering hematopoietic stem cells to improve treatments for blood cancers.
Vor Biopharma (Nasdaq: VOR) announced new data from its eHSC platform at the ASH 63rd Annual Meeting. The data includes the potential of CRISPR-Cas9 gene editing to knock out CD123 and CLL-1, enhancing treatment options for acute myeloid leukemia (AML) patients. Vor's research showcases multiplex genome editing of hematopoietic stem cells, promising safe and efficient gene editing for multiple blood cancer therapies. Presentations will occur from December 11-14, 2021, in Atlanta, Georgia, highlighting the advancements in CAR-T cell therapy and engraftment potential.
Summary not available.
Vor Biopharma (Nasdaq: VOR) announced the appointment of Veit Schmelmer, Ph.D., as Senior Vice President of Program and Alliance Management. With over 25 years in biopharmaceuticals, Dr. Schmelmer will oversee critical programs and lead cross-functional teams to enhance Vor's mission in blood cancer treatment through engineered hematopoietic stem cells. His previous roles include leadership positions at Magenta Therapeutics and Takeda Pharmaceuticals. Vor continues to progress with its Phase 1/2a clinical trial of VOR33, and Dr. Schmelmer's expertise is expected to significantly benefit the company.